GE HealthCare Technologies (NASDAQ:GEHC) Upgraded by The Goldman Sachs Group to “Buy” Rating

The Goldman Sachs Group upgraded shares of GE HealthCare Technologies (NASDAQ:GEHC) from a neutral rating to a buy rating in a research report released on Tuesday, Marketbeat reports. The Goldman Sachs Group currently has $100.00 price objective on the stock, up from their previous price objective of $85.00.

GEHC has been the topic of a number of other research reports. Wells Fargo & Company lifted their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their target price for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Finally, Citigroup lifted their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $98.75.

GE HealthCare Technologies Trading Up 0.3 %

Shares of NASDAQ GEHC opened at $85.59 on Tuesday. The company’s fifty day moving average is $87.06 and its 200-day moving average is $86.17. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The stock has a market cap of $39.14 billion, a price-to-earnings ratio of 19.77, a P/E/G ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies has a twelve month low of $74.51 and a twelve month high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The firm had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. Equities research analysts predict that GE HealthCare Technologies will post 4.68 EPS for the current year.

Institutional Trading of GE HealthCare Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Cherry Creek Investment Advisors Inc. raised its stake in shares of GE HealthCare Technologies by 0.3% during the 4th quarter. Cherry Creek Investment Advisors Inc. now owns 37,351 shares of the company’s stock worth $2,920,000 after purchasing an additional 114 shares in the last quarter. Independence Bank of Kentucky raised its stake in shares of GE HealthCare Technologies by 6.0% during the 4th quarter. Independence Bank of Kentucky now owns 2,018 shares of the company’s stock worth $158,000 after purchasing an additional 114 shares in the last quarter. Haverford Trust Co raised its position in GE HealthCare Technologies by 2.4% during the fourth quarter. Haverford Trust Co now owns 4,896 shares of the company’s stock worth $383,000 after acquiring an additional 115 shares in the last quarter. Tandem Capital Management Corp ADV raised its position in GE HealthCare Technologies by 0.4% during the fourth quarter. Tandem Capital Management Corp ADV now owns 28,210 shares of the company’s stock worth $2,205,000 after acquiring an additional 118 shares in the last quarter. Finally, Arcus Capital Partners LLC raised its position in GE HealthCare Technologies by 3.0% during the fourth quarter. Arcus Capital Partners LLC now owns 4,113 shares of the company’s stock worth $322,000 after acquiring an additional 119 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.